Hélène Peyro-Saint-Paul
Chief Tech/Sci/R&D Officer at QIAGEN MARSEILLE
Profile
Hélène Peyro-Saint-Paul is currently the Chief Medical Officer at QIAGEN Marseille SA since 2009.
Prior to this, she worked as the Chief Medical Officer at MedDay Pharmaceuticals SAS.
She holds a doctorate degree from Université Fédérale Toulouse Midi-Pyrénées, undergraduate and graduate degrees from Université Pierre et Marie Curie, and an MBA from ESSEC Business School, which she received in 2000.
Hélène Peyro-Saint-Paul active positions
Companies | Position | Start |
---|---|---|
QIAGEN MARSEILLE | Chief Tech/Sci/R&D Officer | 26/01/2009 |
Former positions of Hélène Peyro-Saint-Paul
Companies | Position | End |
---|---|---|
MedDay Pharmaceuticals SAS
MedDay Pharmaceuticals SAS BiotechnologyHealth Technology MedDay Pharmaceuticals SAS operates as a biotechnology company developing new drugs for nervous system disorders. The firm operates for the treatment of neuro-metabolic diseases. The company was founded by Frédéric Sedel and Guillaume Brion in 2011 and is headquartered in Paris, France. | Chief Tech/Sci/R&D Officer | - |
Training of Hélène Peyro-Saint-Paul
Université Fédérale Toulouse Midi-Pyrénées | Doctorate Degree |
ESSEC Business School | Masters Business Admin |
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Private companies | 3 |
---|---|
Université Pierre et Marie Curie | Consumer Services |
QIAGEN Marseille SA
QIAGEN Marseille SA Miscellaneous Commercial ServicesCommercial Services QIAGEN Marseille SA is a molecular diagnosis company, which focuses on the development and marketing of diagnostic tests in the field of oncology. Its products are used for diagnosis, prognosis and monitoring of patients with leukemia. The company was founded by Vincent Fert, Stéphane Debono, and Fabienne Hermitte on September 23, 1999 and is headquartered in Marseille, France. | Commercial Services |
MedDay Pharmaceuticals SAS
MedDay Pharmaceuticals SAS BiotechnologyHealth Technology MedDay Pharmaceuticals SAS operates as a biotechnology company developing new drugs for nervous system disorders. The firm operates for the treatment of neuro-metabolic diseases. The company was founded by Frédéric Sedel and Guillaume Brion in 2011 and is headquartered in Paris, France. | Health Technology |
- Stock Market
- Insiders
- Hélène Peyro-Saint-Paul